Literature DB >> 15767513

Contribution of aging to the severity of different motor signs in Parkinson disease.

Gilberto Levy1, Elan D Louis, Lucien Cote, Mario Perez, Helen Mejia-Santana, Howard Andrews, Juliette Harris, Cheryl Waters, Blair Ford, Steven Frucht, Stanley Fahn, Karen Marder.   

Abstract

BACKGROUND: Evidence does not support the view that Parkinson disease (PD) represents an accelerated aging process; however, the additional contribution of aging to the severity of different motor signs in patients with PD is not known. This knowledge may have implications for clinical trials of neuroprotective agents in PD.
OBJECTIVE: To investigate the contribution of aging to the severity of the different motor signs of idiopathic PD.
SETTING: Center for Parkinson Disease and Other Movement Disorders of the Columbia University Medical Center and a neurology clinic that primarily served individuals from the Washington Heights-Inwood community in New York City. PATIENTS: Sample of patients with a wide range of disease duration and age.
DESIGN: Cross-sectional clinic-based study. Patients with PD were evaluated using the Unified Parkinson Disease Rating Scale (UPDRS). The total UPDRS motor score was divided into 6 motor domains (tremor, rigidity, bradykinesia, facial expression, speech, and axial impairment) and 2 subscores that represented predominantly dopaminergic (subscore A: tremor, rigidity, bradykinesia, and facial expression) and nondopaminergic (subscore B: speech and axial impairment) deficiency. Analyses were performed using linear regression models with the UPDRS motor domains and subscores as the outcomes. The variation (adjusted R(2)) of the outcome variables explained by the inclusion of disease duration in the models, adjusting for sex, years of education, levodopa dosage, and use of other antiparkinsonian medications, was calculated. The additional variation explained by adding age at examination to the models was used to gauge the contribution of aging to each motor domain and subscore of the UPDRS.
RESULTS: A total of 451 patients participated in the study. Mean age at examination was 62.0 years (SD, 12.6 years; median, 62.0 years; range, 18-93 years), and mean disease duration was 7.2 years (SD, 5.9 years; median, 5.6 years; range, 0.1-41.6 years). The additional variation of the outcome variable explained by including age in the models was higher for subscore B (14.3%; 95% confidence interval [CI], 9.9%-20.4%) than subscore A (4.7%; 95% CI, 2.0%-9.1%). Among the 6 motor domains, the additional variation of the outcome variable explained by including age in the models was highest for axial impairment (13.6%; 95% CI, 9.4%-19.6%).
CONCLUSION: Axial (gait and postural) impairment in PD may result from the combined effect of the disease and the aging process on nondopaminergic subcortical structures.

Entities:  

Mesh:

Year:  2005        PMID: 15767513     DOI: 10.1001/archneur.62.3.467

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  25 in total

1.  A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.

Authors:  Catherine L Gallagher; Bradley T Christian; James E Holden; Onofre T Dejesus; Robert J Nickles; Laura Buyan-Dent; Barbara B Bendlin; Sandra J Harding; Charles K Stone; Barb Mueller; Sterling C Johnson
Journal:  Mov Disord       Date:  2011-06-02       Impact factor: 10.338

2.  Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease.

Authors:  Vikas Kotagal; Roger L Albin; Martijn L T M Müller; Robert A Koeppe; Kirk A Frey; Nicolaas I Bohnen
Journal:  Neurology       Date:  2014-03-28       Impact factor: 9.910

3.  Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future.

Authors:  Anthony E Lang
Journal:  Nat Med       Date:  2010-09-21       Impact factor: 53.440

4.  Beyond 35 years of Parkinson's disease: a comprehensive clinical and instrumental assessment.

Authors:  Alberto Romagnolo; Margherita Fabbri; Aristide Merola; Elisa Montanaro; Sara Palermo; Tiziana Martone; Agostino Seresini; Stefano Goldwurm; Mario Giorgio Rizzone; Leonardo Lopiano
Journal:  J Neurol       Date:  2018-06-26       Impact factor: 4.849

5.  A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson's disease.

Authors:  Catherine L Gallagher; Sterling C Johnson; Barbara B Bendlin; Moo K Chung; James E Holden; Terrence R Oakes; Benjamin R Brooks; Richard A Konopacki; Selami Dogan; James H Abbs; Guofan Xu; Robert J Nickles; Robert W Pyzalski; Onofre T Dejesus; W Douglas Brown
Journal:  Brain Imaging Behav       Date:  2011-09       Impact factor: 3.978

6.  The impact of motor symptoms on self-reported anxiety in Parkinson's disease.

Authors:  Robert D Salazar; Asher M Le; Sandy Neargarder; Alice Cronin-Golomb
Journal:  Parkinsonism Relat Disord       Date:  2017-01-24       Impact factor: 4.891

7.  Veering in hemi-Parkinson's disease: Primacy of visual over motor contributions.

Authors:  Xiaolin Ren; Robert Salazar; Sandy Neargarder; Serge Roy; Terry D Ellis; Elliot Saltzman; Alice Cronin-Golomb
Journal:  Vision Res       Date:  2015-09-12       Impact factor: 1.886

8.  Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson's disease.

Authors:  Marina Picillo; Roberto Erro; Gabriella Santangelo; Rosario Pivonello; Katia Longo; Claudia Pivonello; Carmine Vitale; Marianna Amboni; Marcello Moccia; Annamaria Colao; Paolo Barone; Maria Teresa Pellecchia
Journal:  J Neurol       Date:  2013-02-12       Impact factor: 4.849

9.  The effect of age of onset of PD on risk of dementia.

Authors:  D Aarsland; J T Kvaløy; K Andersen; J P Larsen; M X Tang; A Lolk; P Kragh-Sørensen; K Marder
Journal:  J Neurol       Date:  2007-02-14       Impact factor: 4.849

10.  Cardiovascular autonomic neuropathy and falls in Parkinson disease: a prospective cohort study.

Authors:  Alberto Romagnolo; Maurizio Zibetti; Aristide Merola; Daniela Canova; Marianna Sarchioto; Elisa Montanaro; Carlo Alberto Artusi; Fabrizio Vallelonga; Simona Maule; Leonardo Lopiano
Journal:  J Neurol       Date:  2018-10-31       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.